Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announced data from two ongoing Phase 2 studies evaluating parsaclisib,
December 7, 2020
· 6 min read